双主业战略

Search documents
杰瑞股份斩获61亿海外大单 深化全球布局净利三连增
Chang Jiang Shang Bao· 2025-07-10 23:41
7月9日晚,杰瑞股份公告,近日,公司的全资子公司JerehOil & Gas Engineering Corporation(杰瑞石油天然气工程 有限公司,以下简称"杰瑞油气工程")收到业主方Sonatrach SPA(阿尔及利亚国家石油公司,以下简 称"Sonatrach")发送的EPC Realization of The Rhourde Nouss Boosting Project(侯德努斯天然气增压站总承包工程 项目)的项目授标函,授标函金额包括美元及阿尔及利亚第纳尔两部分,分别为6.291亿美元和293.58亿阿尔及利 亚第纳尔(合计约8.50亿美元或者61.26亿元人民币)。 杰瑞股份表示,上述项目的中标,标志着公司油气工程服务业务在北非地区的进一步扩张,符合公司聚焦中东及 北非重点地区的发展战略。杰瑞油气工程具备丰富的油气田地面工程技术能力和建设经验,现有的技术、资源能 够满足项目实施需要,若项目正式签署并顺利实施,将有效提升相关市场对公司油气工程板块的业务执行及交付 能力的认可度,有利于公司进一步巩固和拓展在阿尔及利亚乃至整个北非、中东地区陆上油气田一体化开发建设 工程服务市场,强化公司在相关 ...
动力新科子公司上汽红岩申请破产重整:重卡业务困局下的破局尝试
Xin Lang Zheng Quan· 2025-07-10 09:28
动力新科并购时的募投项目也陷入困境。"智慧工厂"项目虽已结项,但"新一代智能重卡"项目进度仅 6.33%,预计2027年才达预定可使用状态。更糟的是,上汽红岩存放在银行的2.8亿元募集资金被法院强 制扣划,原因是金融借款合同纠纷诉讼。 破产重整:债务危机下的唯一出路? 债权人重庆安吉红岩物流的申请理由直指核心:不能清偿到期债务且严重资不抵债,但仍具备重整价值 及可行性。这一判断基于上汽红岩的技术资产:其拥有全球首张智能网联重卡示范运营牌照,纯电动牵 引车通过欧盟认证,成为全国首家将纯电重卡出口到国外的企业。2025年4月,公司曾与多家物流企业 签订重启生产订单。 对动力新科而言,重整若成功实施,将直接化解上汽红岩的债务包袱。根据动力新科公告,2025年一季 度其货币资金同比减少24.43%至40.96亿元,资产负债率攀升至74.90%。剥离亏损源后,公司可集中资 源发展发动机与发动机配件业务。 2025年7月1日,上海新动力汽车科技股份有限公司(简称"动力新科(维权)",股票代码600841.SH) 一纸公告震动资本市场:其全资子公司上汽红岩汽车有限公司被债权人重庆安吉红岩物流有限公司向重 庆市第五中级人民法 ...
英联股份江苏总部基地落成在即 双主业战略再添新引擎
Zheng Quan Shi Bao Wang· 2025-06-30 12:14
Core Viewpoint - Yinglian Co., Ltd. is accelerating the development of its composite current collector business, marking a significant step in its dual-driven strategy of "fast-moving consumer goods metal packaging + new energy materials" [2][3] Group 1: Business Development - Yinglian Co., Ltd. is a leading manufacturer of easy-open lids in China, listed on the Shenzhen Stock Exchange in 2017, and is the first listed company in this sector [3] - The company is focusing on both its fast-moving consumer goods metal packaging business and the composite current collector business, implementing a dual main business model [3][6] - The total investment for the new energy power lithium battery composite current collector project is 3.089 billion yuan, with plans to build 10 production lines for composite aluminum foil and 134 production lines for composite copper foil, aiming for an annual production capacity of 100 million m² of composite aluminum foil and 500 million m² of composite copper foil upon reaching full capacity [3][4] Group 2: Technological Advancements - Yinglian Co., Ltd. has successfully developed PET and PP-based composite copper foil and composite aluminum foil, which are currently in the customer verification stage, with bulk orders expected from South Korean client U&SENERGY by December 2024 [3][4] - The company has introduced five production lines from Japan for composite aluminum foil and five production lines utilizing "magnetron sputtering + electroplating" technology for composite copper foil [4] - The company is collaborating with a well-known automotive company and a leading consumer battery enterprise to develop next-generation battery technologies, with its composite current collector materials entering testing for solid-state battery applications [4][6] Group 3: Strategic Significance - The completion of the headquarters base in Jiangsu is significant for large-scale production and aims to position the company as a "global leader in composite current collector solutions" [5] - The event gathered industry experts and upstream and downstream enterprises to promote deep exchanges in material processes and production equipment, enhancing the international competitiveness of domestic materials [5] - The project leverages local industrial infrastructure and government support in the Gaoyou Economic Development Zone, facilitating cooperation between government and enterprises to upgrade the energy industry [5][6]
探路者20250603
2025-06-04 01:50
探路者 20250603 自 2021 年 2 月公司控制权变更以来,探路者在 9 月切入芯片赛道,并逐步夯 实双主业战略。根据 2024 年的年报,芯片收入占比约 15%,利润占比达 30%。自新管理层接手以来,公司业绩逐年向上:从 2020 年的亏损 2.74 亿 元,到 21 年的盈利约 5,500 万元,再到 22 年的六七千万元、23 年的 7,200 万元,以及 24 年的 1.06 亿元。这表明我们的双主业战略正在稳步推进并取得 显著成效。 探路者在产品结构调整及市场定位上的具体措施有哪些? 在产品结构调整方面,我们聚焦户外专业线,推出黑麦系列和极地系列,以满 足高端市场需求。同时,通过加强价格体系管理、提升产品折扣等措施,提高 整体毛利率。在市场定位上,我们重新梳理品牌定位,坚持走高端路线,并通 过严格选址与投入确保线下门店扩展的成功率。此外,在儿童装领域加大培育 力度,看好其未来增长潜力。 摘要 探路者自 2021 年控制权变更后,确立"户外用品+芯片"双主业战略, 2024 年芯片业务收入占比约 15%,利润占比达 30%,公司整体业绩逐 年提升,2024 年净利润达 1.06 亿元。 公 ...
棒杰股份(002634) - 002634棒杰股份投资者关系管理信息20250513
2025-05-13 10:00
1 尊敬的投资者您好,感谢您对公司的关注。2024 年,公司继续保持 "无缝服装+光伏"双主业的业务结构,无缝服装实现营业收入 6.20 亿 元,占总营业收入比重为 56.06%;光伏产品实现营业收入 4.52 亿元,占 总营业收入比重为 40.86%,谢谢! 3、无缝服装作为公司优势业务,请介绍一下公司 2025 年度的重点 工作? 您好,感谢您对公司的关注。2025 年,公司将继续加强无缝服装业 务的新品开发和技术创新力度,提升智能化制造水平,积极开拓国内外 市场,在保持和巩固与现有客户良好合作关系的基础上,积极开发优质 新客户,深入挖掘潜力市场。同时加强营销队伍建设,创新发展理念, 巩固和扩大市场份额,争创更好业绩。谢谢! 4、公司好,请介绍一下公司未来发展战略规划,谢谢! 证券代码:002634 证券简称:棒杰股份 浙江棒杰控股集团股份有限公司投资者关系活动记录表 编号:2025-001 | | □特定对象调研 | □分析师会议 | | --- | --- | --- | | | □媒体采访 | √业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | ...
尔康制药2024年度业绩说明会:双主业战略显效 非洲锂矿项目成业绩增长新引擎
Quan Jing Wang· 2025-05-13 01:29
Core Viewpoint - The company is focusing on a dual business strategy of "pharmaceuticals + new energy materials," with significant growth driven by the African lithium mining project and technological innovation [1][6]. Group 1: Dual Business Strategy - In Q1 2025, the company achieved a net profit of 28.11 million yuan, a substantial increase of 868.91% year-on-year, primarily due to the operational capacity release of the lithium processing plant in Nigeria and cost optimization [2]. - The lithium mining project is a key step in implementing the dual business strategy, with the first processing plant in Nigeria now operating stably, and future expansion plans will be evaluated based on market demand [2]. Group 2: Pharmaceutical Sector - The company is increasing its R&D efforts, with 13 new patents added in 2024, including 2 invention patents, and steady progress in the development of heart failure drugs [3]. - The company is also expanding into overseas markets, with a pharmaceutical company established in Tanzania and a factory in Cambodia entering production [3]. Group 3: Regulatory Impact on Pharmaceutical Excipients - The implementation of new quality management regulations for pharmaceutical excipients is expected to enhance the company's market capacity and competitiveness [4]. - The regulations emphasize the responsibility of excipient manufacturers for product quality and require stricter management and oversight processes [4]. Group 4: Technological Innovation - The company has established new technology ventures focusing on electronic components and AI applications, indicating a strategic move towards integrating technology with its core business [5]. - There is a strong emphasis on AI and intelligent technology applications in the pharmaceutical excipient manufacturing sector, with plans to build an AI innovation platform [5]. Group 5: Future Outlook - The company aims to continue strengthening its dual business strategy, enhancing technological innovation, optimizing resource allocation, and improving operational efficiency to achieve steady growth in business performance [6]. - The clear strategic planning and proactive innovation spirit position the company well for high-quality development in a complex market environment [6].
汉商集团2024年实现营收11.75亿元 原创研发有望带动业绩回升
Jing Ji Guan Cha Bao· 2025-04-30 00:39
4月29日晚间,汉商集团(600774.SH)发布2024年年报,财务数据显示,报告期内,公司实现营业收 入11.75亿元,比去年同期同比减少15.41%。 在辅助生殖业务板块,汉商集团表示,将加大对辅助生殖科重点学科的支持力度,打造具有较高知名度 和影响力的特色学科群,持续优化医疗服务,积极推进杨泗港新院区建设,有望建成国内知名的生殖专 科医院。 商业会展板块,一方面,汉商集团旗下各购物中心、经营公司关注市场变化,通过深度结构调改激活消 费市场需求,同时逐步拓展国际贸易、消费品供应链业务,试水低空物流等新型业务,保持商业板块竞 争活力。作为代表性的调改项目之一,汉商集团将旗下原武汉婚纱照材城改造为汉潮Z6项目,该项目 比邻江汉路商圈,定位一站式次元文化体验中心,未来聚焦年轻客群。另一方面,武汉国际会展中心深 化经营转型升级和创新,该展览中心抓住"大会展"产业体系建设契机,双馆联动,错位发展,构建会展 场馆服务新格局。 据了解,报告期内,汉商集团营收的下滑,主要源于市场环境波动及相关医疗业政策调整带来的医药板 块收入减少。汉商集团方面表示,随着"大健康+大商业"双主业战略的深耕布局,2025年公司业绩有望 迎 ...
大东方收盘上涨3.35%,滚动市盈率33.24倍,总市值43.62亿元
Sou Hu Cai Jing· 2025-04-10 11:09
4月10日,大东方今日收盘4.93元,上涨3.35%,滚动市盈率PE(当前股价与前四季度每股收益总和的比 值)达到33.24倍,总市值43.62亿元。 从行业市盈率排名来看,公司所处的医疗服务行业市盈率平均46.62倍,行业中值44.83倍,大东方排名 第25位。 来源:金融界 最新一期业绩显示,2024年三季报,公司实现营业收入27.62亿元,同比2.87%;净利润1.01亿元,同 比-23.08%,销售毛利率14.93%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)25大东方33.2427.021.3343.62亿行业平均 46.6242.163.39143.31亿行业中值44.8336.172.4845.23亿1普瑞眼科-197.9724.752.9966.30亿2何氏眼 科-148.4345.501.4928.92亿3迪安诊断-94.6028.481.2487.56亿4光正眼科-87.47207.837.0519.24亿5创新医 疗-80.49-112.482.0938.57亿6南华生物-75.94-99.9211.3228.15亿7国际医学-33.01-32.093.24118.22亿8 ...